Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8/9 and arginase and suppress T cell function

被引:126
作者
Gielen, Paul R. [1 ]
Schulte, Barbara M. [1 ]
Kers-Rebel, Esther D. [1 ]
Verrijp, Kiek [2 ]
Bossman, Sandra A. J. F. H. [3 ]
ter Laan, Mark [3 ]
Wesseling, Pieter [2 ,4 ]
Adema, Gosse J. [1 ]
机构
[1] Radboud Inst Mol Life Sci, Tumor Immunol Lab, Nijmegen, Netherlands
[2] Radboud Univ Nijmegen, Med Ctr, Dept Pathol, Nijmegen, Netherlands
[3] Radboud Univ Nijmegen, Med Ctr, Dept Neurosurg, Nijmegen, Netherlands
[4] Vrije Univ Amsterdam, Med Ctr, Dept Pathol, Amsterdam, Netherlands
关键词
arginase; glioma; MDSCs; S100A8/9; DIFFUSE GLIOMAS; GASTRIC-CANCER; SURVIVAL; IMMUNOTHERAPY; RAGE; SUBPOPULATIONS; ACCUMULATION; TEMOZOLOMIDE; PROGRESSION; INHIBITION;
D O I
10.1093/neuonc/now034
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Gliomas are primary brain tumors that are associated with a poor prognosis. The introduction of new treatment modalities (including immunotherapy) for these neoplasms in the last 3 decades has resulted in only limited improvement in survival. Gliomas are known to create an immunosuppressive microenvironment that hampers the efficacy of (immuno) therapy. One component of this immunosuppressive environment is the myeloid-derived suppressor cell (MDSC). Methods. We set out to analyze the presence and activation state of MDSCs in blood (n = 41) and tumor (n = 20) of glioma patients by measuring S100A8/9 and arginase using flow cytometry and qPCR. Inhibition of T cell proliferation and cytokine production after stimulation with anti-CD3/anti-CD28 coated beads was used to measure in vitro MDSC suppression capacity. Results. We report a trend toward a tumor grade-dependent increase of both monocytic (M-) and polymorphonuclear (PMN-) MDSC subpopulations in the blood of patients with glioma. M-MDSCs of glioma patients have increased levels of intracellular S100A8/9 compared with M-MDSCs in healthy controls (HCs). Glioma patients also have increased S100A8/9 serum levels, which correlates with increased arginase activity in serum. PMN-MDSCs in both blood and tumor tissue demonstrated high expression of arginase. Furthermore, we assessed blood-derived PMN-MDSC function and showed that these cells have potent T cell suppressive function in vitro. Conclusions. These data indicate a tumor grade-dependent increase of MDSCs in the blood of patients with a glioma. These MDSCs exhibit an increased activation state compared with MDSCs in HCs, independent of tumor grade.
引用
收藏
页码:1253 / 1264
页数:12
相关论文
共 48 条
[1]   Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein [J].
Cheng, Pingyan ;
Corzo, Cesar A. ;
Luetteke, Noreen ;
Yu, Bin ;
Nagaraj, Srinivas ;
Bui, Marylin M. ;
Ortiz, Myrna ;
Nacken, Wolfgang ;
Sorg, Clemens ;
Vogl, Thomas ;
Roth, Johannes ;
Gabrilovich, Dmitry I. .
JOURNAL OF EXPERIMENTAL MEDICINE, 2008, 205 (10) :2235-2249
[2]   Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes [J].
de Kok, JB ;
Roelofs, RW ;
Giesendorf, BA ;
Pennings, JL ;
Waas, ET ;
Feuth, T ;
Swinkels, DW ;
Span, PN .
LABORATORY INVESTIGATION, 2005, 85 (01) :154-159
[3]   Myeloid-derived suppressor cells as therapeutic target in hematological malignancies [J].
De Veirman, Kim ;
Van Valckenborgh, Els ;
Lahmar, Qods ;
Geeraerts, Xenia ;
De Bruyne, Elke ;
Menu, Eline ;
Van Riet, Ivan ;
Vanderkerken, Karin ;
Van Ginderachter, Jo A. .
FRONTIERS IN ONCOLOGY, 2014, 4
[4]   Macrophage/microglial cell subpopulations in glioblastoma multiforme relapses are differentially altered by radiochemotherapy [J].
Deininger, MH ;
Pater, S ;
Strik, H ;
Meyermann, R .
JOURNAL OF NEURO-ONCOLOGY, 2001, 55 (03) :141-147
[5]   Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy [J].
Diaz-Montero, C. Marcela ;
Salem, Mohamed Labib ;
Nishimura, Michael I. ;
Garrett-Mayer, Elizabeth ;
Cole, David J. ;
Montero, Alberto J. .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2009, 58 (01) :49-59
[6]  
Dietrich Jorg, 2011, Expert Rev Clin Pharmacol, V4, P233, DOI 10.1586/ecp.11.1
[7]   The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer [J].
Ehrchen, Jan M. ;
Sunderkoetter, Cord ;
Foell, Dirk ;
Vogl, Thomas ;
Roth, Johannes .
JOURNAL OF LEUKOCYTE BIOLOGY, 2009, 86 (03) :557-566
[8]   Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. [J].
Fecci, PE ;
Mitchell, DA ;
Whitesides, JF ;
Xie, WH ;
Friedman, AH ;
Archer, GE ;
Herndon, JE ;
Bigner, DD ;
Dranoff, G ;
Sampson, JH .
CANCER RESEARCH, 2006, 66 (06) :3294-3302
[9]   CD14+S100A9+ Monocytic Myeloid-derived Suppressor Cells and Their Clinical Relevance in Non-Small Cell Lung Cancer [J].
Feng, Po-Hao ;
Lee, Kang-Yun ;
Chang, Ya-Ling ;
Chan, Yao-Fei ;
Kuo, Lu-Wei ;
Lin, Ting-Yu ;
Chung, Fu-Tsai ;
Kuo, Chih-Shi ;
Yu, Chih-Teng ;
Lin, Shu-Min ;
Wang, Chun-Hua ;
Chou, Chun-Liang ;
Huang, Chien-Da ;
Kuo, Han-Pin .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2012, 186 (10) :1025-1036
[10]   Immunotherapy for glioma: getting closer to the clinical arena? [J].
Finocchiaro, Gaetano ;
Pellegatta, Serena .
CURRENT OPINION IN NEUROLOGY, 2011, 24 (06) :641-647